title: SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma.
abstract: By using the GRADE system, we updated the guidelines for management of follicular cell lymphoma issued in 2006 from SIE, SIES, and GITMO group. We confirmed our recommendation to frontline chemoimmunotherapy in patients with Stage III-IV disease and/or high tumor burden. Maintenance rituximab was also recommended in responding patients. In patients relapsing after an interval longer than 12 months from frontline therapy, we recommended chemoimmunotherapy with non cross-resistant regimens followed by rituximab maintenance. High dose chemotherapy followed by hematopoietic stem cell transplant was recommended for young fit patients who achieve a response after salvage chemoimmunotherapy.
authors: Istituto di Ematologia ed Oncologia Medica Seragnoli, Università di Bologna, Bologna, Italy.
authors: Pier Luigi
authors: PL
authors: Zinzani
authors: Monia
authors: M
authors: Marchetti
authors: Atto
authors: A
authors: Billio
authors: Giovanni
authors: G
authors: Barosi
authors: Angelo Michele
authors: AM
authors: Carella
authors: Mario
authors: M
authors: Lazzarino
authors: Maurizio
authors: M
authors: Martelli
authors: Alessandro
authors: A
authors: Rambaldi
authors: Luigi
authors: L
authors: Rigacci
authors: Corrado
authors: C
authors: Tarella
authors: Umberto
authors: U
authors: Vitolo
authors: Sante
authors: S
authors: Tura
mesh_terms: D000328:Adult; D058846:Antibodies, Monoclonal, Murine-Derived / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D019468:Disease Management; D004334:Drug Administration Schedule; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007167:Immunotherapy; D008224:Lymphoma, Follicular / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D000069283:Rituximab; D055502:Secondary Prevention; D013997:Time Factors
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab